Headlines about Enzymotec (NASDAQ:ENZY) have trended positive on Saturday, Accern Sentiment reports. Accern identifies positive and negative press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Enzymotec earned a news sentiment score of 0.43 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 96 out of 100, meaning that recent press coverage is extremely likely to have an impact on the company’s share price in the immediate future.
Separately, Zacks Investment Research upgraded shares of Enzymotec from a “strong sell” rating to a “hold” rating in a research report on Friday, April 28th.
Shares of Enzymotec (ENZY) traded up 0.63% during midday trading on Friday, reaching $8.05. 29,035 shares of the company were exchanged. The stock’s market capitalization is $184.34 million. The company’s 50-day moving average price is $7.75 and its 200 day moving average price is $8.34. Enzymotec has a 52-week low of $5.20 and a 52-week high of $9.32.
Enzymotec (NASDAQ:ENZY) last posted its earnings results on Wednesday, May 17th. The biotechnology company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.06 by $0.03. Enzymotec had a negative return on equity of 2.06% and a negative net margin of 9.50%. The firm had revenue of $12 million during the quarter, compared to the consensus estimate of $14.23 million. During the same quarter last year, the company posted $0.09 EPS. Enzymotec’s revenue for the quarter was down 14.3% on a year-over-year basis. On average, equities analysts predict that Enzymotec will post $0.21 earnings per share for the current year.
Enzymotec Company Profile
Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.
Receive News & Ratings for Enzymotec Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.